BioMerieux SA

EYWN

Company Profile

  • Business description

    BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

  • Contact

    Marcy l’Etoile
    Lyon69280
    FRA

    T: +33 478872000

    E: [email protected]

    http://www.biomerieux.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    14,754

Stocks News & Analysis

stocks

Ask the analyst: How reliant are Guzman shares on international growth?

A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks

Nvidia: Back in business in China; Raising fair value estimate

Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,816.4058.90-0.66%
CAC 407,722.0944.12-0.57%
DAX 4024,009.3850.91-0.21%
Dow JONES (US)44,245.26221.970.50%
FTSE 1008,926.5511.77-0.13%
HKSE24,517.7672.36-0.29%
NASDAQ20,737.0559.250.29%
Nikkei 22539,663.4014.62-0.04%
NZX 50 Index12,754.5964.960.51%
S&P 5006,265.1721.410.34%
S&P/ASX 2008,561.8068.50-0.79%
SSE Composite Index3,503.781.22-0.03%

Market Movers